Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from CardieX ( (AU:CDX) ) is now available.
Cardiex Limited has announced the dispatch of its Entitlement Offer Booklet for a fully underwritten non-renounceable pro rata entitlement offer of new shares. The offer aims to raise approximately $4.1 million before costs, with a closing date set for June 20, 2025. This initiative is expected to strengthen Cardiex’s financial position and support its ongoing efforts in advancing vascular health technologies.
More about CardieX
Cardiex is a company focused on medical technology advancements in vascular health. It offers a range of products including medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders, leveraging its SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange (ASX:CDX).
Average Trading Volume: 245,823
Technical Sentiment Signal: Sell
Current Market Cap: A$22.33M
Learn more about CDX stock on TipRanks’ Stock Analysis page.